Abstract
Breast cancer is the leading malignant disease in women in the Western world. It affects 9–12% of women during their lifetime (Heywang-Köbrunner and Schreer 2003). In the United States breast cancer causes more than 43,000 deaths per year, in the countries of the European Union more than 74,000 (Eurostat Datenbank Newcronos, unpublished data). Early detection and effective treatment of breast cancer are the major factors contributing to the decline in the mortality rate. At present, mammography is the gold standard for the detection of breast cancer. Despite recent technical advances, mammography may miss as many as 10–25% of carcinomas, particularly in radiographically dense breasts. Furthermore, the high rate of false-positive mammograms (60–70%) results in a correspondingly high rate of biopsies that impose a heavy psychological burden on women and a heavy financial cost on the healthcare system (Heywang-Köbrunner and Schreer 2003; Elmore et al. 1998). Various additional modalities such as ultrasound (US) or magnetic resonance imaging (MRI) have been introduced to adjunctively either increase cancer detection or to improve discrimination between malignant and benign lesions. Despite complementary use of these imaging modalities, breast cancer is missed in a considerable number of cases (Heywang-Köbrunner and Schreer 2003; Elmore et al. 1998). Over time, substantial insight into the pathophysiology of breast carcinomas and other breast diseases has been gained. This knowledge should be included in breast imaging strategies of the future. Researchers expect to gain more, and particularly more precise and specific, information about breast lesions in the future, leading to earlier diagnosis of breast cancer and a more precise discrimination between benign and malignant tumors.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
American College of Radiology (2003) Illustrated breast imaging reporting and data system (BI-RADS): ultrasound, 1st edn. American College of Radiology, Reston, VA
Bremer C, Ntziachristos V, Weitkamp B, Theilmeier G, Heindel W, Weissleder R (2005) Optical imaging of spontaneous breast tumors using protease sensing ‘smart’ optical probes. Invest Radiol 40:321–327
Buchberger W, Niehoff A, Obrist P, DeKoekkoek-Doll P, Dunser M (2000) Clinically and mammographically occult breast lesions: detection and classification with high-resolution sonography. Semin Ultrasound CT MR 21(4):325–336
Daldrup-Link HE, Brasch RC(2003)Macromolecular contrast agents for MR mammography: current status. Eur Radiol 13:354–365
Daldrup-Link HE, Rydland J, Helbich TH et al (2003) Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. Radiology 229:885–892
Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW (1998) Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338:1089–1096
Floery D, Helbich TH, Riedl CC et al (2005) Characterization of benign and malignant breast lesions with computed tomography laser mammography (CTLM): initial experience. Invest Radiol 328–335
Fricke H, Morse S (1926) The electric capacity of tumors in the breast. J Cancer Res 16:340–376
Fuchsjäger MH, Helbich TH, Ringl H et al (2002) Electrical impedance scanning in the differentiation of suspicious breast lesions: comparison with mammography, ultrasound and histopathology. Fortschr Röntgenstr 174:1522–1529
Fuchsjäger M, Diebold T, Szabo B, Malich A, Vogl T, Helbich T (2003) Electrical impedance scanning European multicenter evaluation: final definition of adjunctive value to mammography and sonography for differentiation of malignant and benign breast lesions. Radiology 229:513
Fuchsjäger MH, Flory D, Reiner CS, Rudas M, Riedl CC, Helbich TH (2005) The negative predictive value of electrical impedance scanning in BI-RADS category IV breast lesions. Invest Radiol 40:478–485
Funovics MA, Kapeller B, Hoeller C et al (2004) MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 22:843–850
Helbich TH (2000) Contrast-enhanced magnetic resonance imaging of the breast. Eur J Radiol 34:208–219
Heywang-Köbrunner SH, Schreer I (2003) Bildgebende Mammadiagnostik, 2nd ed. Thieme, New York
Hogemann-Savellano D, Bos E, Blondet C et al (2003) The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 5:495–506
Jossinet J (1996) Variability of impeditivity in normal and pathological breast tissue. Med Biol Eng Comput 34:346–350
Jossinet J (1998) The impeditivity of freshly excised human breast tissue. Physiol Meas 19:61–75
Ke S, Wen X, Gurfinkel M et al (2003) Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 63:7870–7875
Kolb TM, Lichy J, Newhouse JH (2002) Comparison of the performance of screening mammography, physical examination and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 225:165–175
Kuhl CK, Jost P, Morakkabati N, Zivanovic O, Schild HH, Gieseke J (2006) Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. Radiology 239: 666–676
Kumar R, Alavi A (2004) Fluorodeoxyglucose-PET in the management of breast cancer. Radiol Clin N Am 42:1113–1122, ix
Leconte I, Feger C, Galant C, Berliere M, Vande Berg B, D’Hoore W, Maldague B (2003) Mammography and subsequent whole-breast sonography of nonpalpable breast cancers: the importance of radiologic breast density. AJR Am J Roentgenol 180:1675–1679
Linden HM, Stekhova SA, Link JM et al (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24:2793–2799
Madjar H, Ohlinger R, Mundinger A, Watermann D, Frenz JP, Bader W, Schulz-Wendtland R, Degenhardt F (2006) BI-RADS-analogue DEGUM criteria for findings in breast ultrasound – consensus of the DEGUM committee on breast ultrasound Ultraschall Med 27:374–379
Malich A, Böhm T, Facius M et al (2001) Additional value of electrical impedance scanning: experience of 240 histologically-proven breast lesions. Eur J Cancer 37:2324–2330
Moon WK, Chang RF, Chen CJ, Chen DR, Chen WL (2005) Solid breast masses: classification with computer-aided analysis of continuous US images obtained with probe compression. Radiology 236:458–464
Ntziachristos V, Yodh AG, Schnall M, Chance B (2000) Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci U S A 97:2767–2772
Perlet C, Kessler M, Lenington S, Sittek H, Reiser M (2000) Electrical impedance measurement of the breast: effect of hormonal changes associated with the menstrual cycle. Eur Radiol 10:1550–1554
Piperno G, Frei E, Moshitzky M (1990) Breast cancer screening by impedance measurements. Front Med Biol Eng 2:111–117
Rizzatto G (2001) Towards a more sophisticated use of breast ultrasound. Eur Radiol 11:2425–2435
Robinson MK, Doss M, Shaller C et al (2005) Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 65:1471–1478
Rotten D, Levaillant J-M, Zerat L (1999) Analysis of normal breast tissue and of solid breast masses using three-dimensional ultrasound mammography. Ultrasound Obstet Gynecol 14:114–124
Smyczek-Gargya B, Fersis N, Dittmann H et al (2004) PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 31:720–724
Stojadinovic A, Nissan A, Gallimidi Z, Lenington S, Logan W, Zuley M, Yeshaya A, Shimonov M, Melloul M, Fields S, Allweis T, Ginor R, Gur D, Shriver CD (2005) Electrical impedance scanning for the early detection of breast cancer in young women: preliminary results of a multicenter prospective clinical trial. J Clin Oncol 23:2703–2715
Surowiec AJ, Stuchly SS, Barr JR et al (1988) Dielectric properties of breast carcinoma and the surrounding tissues. IEEE Trans Biomed Eng 35:257–263
Tung CH (2000) In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res 60 Sept 1, 4953–58
Weismann CF (2000) Breast ultrasound: new frontiers in imaging? Ultrasound Obstet Gynecol 15:279–281
Weismann CF (2005) Recent advances in multidimensional 3D/4D breast imaging. In: Ueno E, Shiina T, Kubota M, Sawai K (eds) Research and development in breast ultrasound. Springer, Tokyo, pp 146–150
Woodhams R (2005) ADC mappring of benign and malignant breast tumors. Magn Reson Med Sci 4(1):35–42
Yagle KJ, Eary JF, Tait JF et al (2005) Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 46:658–666
Zou Y, Guo Z (2003) A review of electrical impedance techniques for breast cancer detection. Med Eng Physiol 25:79–90
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Flöry, D., Fuchsjaeger, M.W., Weisman, C.F., Helbich, T.H. (2009). Advances in Breast Imaging: A Dilemma or Progress?. In: Brun del Re, R. (eds) Minimally Invasive Breast Biopsies. Recent Results in Cancer Research, vol 173. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-31611-4_10
Download citation
DOI: https://doi.org/10.1007/978-3-540-31611-4_10
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-31403-5
Online ISBN: 978-3-540-31611-4
eBook Packages: MedicineMedicine (R0)